Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.38 |
| ▸ | HTR2A | P28223 | 11/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420499 | 0.86 | HTR2C (0.38) | HTR2CHTR2AHTR6HTR7PIM1 | |
| SCHEMBL4421142 | 0.83 | ALDH1A1 (0.36) | HTR2CHTR2AHTR6HTR2BNPC1 | |
| SCHEMBL4557945 | 0.68 | CYP1A1 (0.47) | PIM1 | |
| Hydrochloric Acid SCHEMBL9573826 | 0.67 | HTR2C (0.65) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL4591697 | 0.64 | HTR2A (0.45) | HTR2CHTR2AHTR6HTR7 | |
| SCHEMBL6294206 | 0.63 | HTR2C (0.74) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL9382041 | 0.60 | PRKCA (0.63) | — | |
| SCHEMBL613000 | 0.60 | MEN1 (0.54) | HTR2CHTR2AREN | |
| Hydrochloric Acid SCHEMBL9573793 | 0.59 | HTR2C (0.51) | HTR2CHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL7097944 | 0.59 | HTR2C (0.51) | HTR2CHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PIK3C2A | HTR2C 826/4885HTR2A 780/4885HTR6 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.